Ignite Creation Date:
2024-05-05 @ 11:35 AM
Last Modification Date:
2024-10-26 @ 9:10 AM
Study NCT ID:
NCT00083954
Status:
COMPLETED
Last Update Posted:
2013-01-04
First Post:
2004-06-03
Brief Title:
Controlled Study of the Use of Quetiapine Fumarate in the Treatment of Patients With Bipolar Depression
Sponsor:
AstraZeneca
Organization:
AstraZeneca
Study Overview
Official Title:
A Confirmatory Multicenter Double-blind Randomized Placebo Controlled Study of the Use of Quetiapine Fumarate SEROQUEL in the Treatment of Patients With Bipolar Depression
Status:
COMPLETED
Status Verified Date:
2013-01
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to determine the efficacy of quetiapine compared to placebo in the treatment for a major depressive episode in patients with bipolar disorder after receiving treatment for up to 8 weeks
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None